Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients

Journal of Clinical Psychopharmacology

Volumn 22, Issue 5, 2002, Pages 481-486

  Solai, LalithKumar K ^a   Pollock, Bruce G ^a   Mulsant, Benoit H ^a   Frye, Reginald F ^a   Miller, Mark D ^a   Sweet, Robert A ^a   Kirshner, Maggie ^a   Sorisio, Denise ^a   Begley, Amy ^a   Reynolds III, Charles F ^a  

^a W Psychiatric Institute and Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEBRISOQUINE; NORTRIPTYLINE; PAROXETINE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GERIATRIC PATIENT; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VOLUNTEER;

EID: 0036784995     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200210000-00007     Document Type: Article

References (31)

1. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-87.
2. Evans DAP, Mahgroup A, Sloan TP, et al. A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. Med Genet 1980;17:102-05.
3. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allelic frequencies and phenotypic consequences. Am J Human Genet 1997;60:284-95.
4. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1994a;2:204-13.
5. Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing. Drugs 1989;37:105-12.
6. Schmider J, Greenblatt DJ, Fogelman SM, et al. Metabolism of dextromethorphan in vitro: involvement of cytochrome P450 2D6 and 3A3/4 with a possible role of 2E1. Biopharm Drug Dispos 1997;18:227-40.
7. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: role of CYP 2C9, CYP 2C19, CYP 2D6 and CYP 3A. J Pharm Pharmacol 1998;50:997-1004.
8. Frye RF, Matzke GR, Adedoyin A, et al. Validation of the Pittsburgh cocktail approach to assess selective regulation of drug metabolizing enzymes. Clin Pharmacol Ther 1997;62:365-76.
9. Labbe L, Sirios C, Pilote S, et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000;10:425-38.
10. Pollock BG, Perel J, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992a;28:163-8.
11. Kaisary A, Smith P, Jaczq E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987;47:5488-93.
12. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications with enzyme-inducing drugs. J Clin Pharmacol 1999;39:567-77.
13. Sindrup SH, Brosen K, Gram L. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
14. Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000;40:58-66.
15. Ozdemir V, Naranjo CA, Shulman RW, et al. Determinants of interindividual variability and extent of CYP 2D6 and CYP 1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998;18:198-207.
16. Yoon YR, Cha IJ, Shon JH, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 2000;67:567-76.
17. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psych Scand 1989;350[Suppl]:60-75.
18. Mulsant BH, Pollock BG, Nebes R, et al. A 12-week double-blind randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001;9:406-14.
19. First MB, Gibbon M, Spitzer RL, et al. Structured clinical interview for DSM-IV axis I disorders, SCID I: clinical version, administration booklet. Washington, DC: American Psychiatric Press, 1997.
20. Mulsant BH, Sweet RA, Rifai AH, et al. The use of the Hamilton Rating Scale for Depression in elderly patients with cognitive impairment and physical illness. Am J Geriatr Psychiatry 1994;2: 220-9.
21. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-48.
22. Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry 1991;148:102-5.
23. Peart GF, Boutagy J, Shenfield GM. Debrisoquine oxidation in Australian population. Br J Clin Pharmacol 1986;21:465-71.
24. Harrison PM, Tonkin AM, Dixon ST, et al. Determination of debrisoquine and its 4-hydroxymetabolite in urine by high-performance liquid chromatography. J Chromatogr 1986;374:204-8.
25. Pollock BG, Everett G, Peril JM. Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacology 1992b;6:1-10.
26. Foglia JP, Sorisio D, Kirshner M, et al. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Appl 1997;693[Suppl]:147-51.
27. DeVane LC, Pollock BG. Pharmacokinetic considerations of antidepressants use in the elderly. J Clin Psychiatry 1999;60[Suppl 20]:38-44.
28. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP 2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
29. Otton SV, Inaba, T, Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 1983;32:795-800.
30. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psycopharmacol 1997;17:284-91.
31. Alfaro CL, Lam YW, Simpson J, et al. CYP 2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999;19:155-63.